arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

Jin Medical International Ltd.

ZJYL

$2.03 ▲ +0.16 (+8.56%) at close

5 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

Jin Medical International Ltd. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $317.8M

Dividend Yield —

Revenue Growth -12.0% ↘

Op. Margin 2.9% ↘

ROIC 1.8% ↘

FCF / Share $-0.02 ↘

Trailing P/E 203.0x

Price / Book 10.7x

FCF Yield —

Debt / Equity 0.64

info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$20.69M

↓ -12.0% —

Net Income Profit after all expenses

$1.19M

↓ -67.6% —

Operating Margin Operating profit as % of sales

2.9%

↓ -81.0% 36th

FCF / Share Free cash flow per share

$-0.02

↓ -175.4% —

Health Breakdown

Profitability ↓

Returns ↓

Financial Health →

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗
Revenue Growth YoY (%)	-12.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-250%)	18.6% Good ↑ Good Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+132%)	3.3% Caution Caution Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-59%)	-7.6% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-195%)	—
EPS Growth YoY (%)	-50.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution → Caution Stable Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	-67.6% Weak ↓ Weak Declining Year-over-year change in net income	27.7% Excellent ↑ Excellent Improving Year-over-year change in net income	6.3% Fair Fair Year-over-year change in net income	2.8% Caution Caution Year-over-year change in net income	—
FCF Growth YoY (%)	-175.4% Weak ↓ Weak Declining Year-over-year change in free cash flow	N/M	80.7% Excellent Excellent Year-over-year change in free cash flow	-73.4% Weak Weak Year-over-year change in free cash flow	—
Revenue CAGR 3Y (%)	2.5% Caution Caution Compound annual revenue growth over 3 years	4.2% Caution Caution Compound annual revenue growth over 3 years	—	—	—
EPS CAGR 3Y (%)	-20.6% Weak Weak Compound annual EPS growth over 3 years	0.0% Caution Caution Compound annual EPS growth over 3 years	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗
Operating Margin (%) (%)	2.9% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-80%)	15.5% Fair ↑ Fair Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: At sector avg	14.5% Fair ↑ Fair Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: At sector avg	11.1% Caution Caution Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-26%)	12.7% Fair Fair Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-16%)
Effective Tax Rate (%) (%)	13.4% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	18.3% Good ↑ Good Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	10.7% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	8.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%
Profit Margin (%) (%)	5.8% Caution ↓ Caution Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-52%)	15.6% Good ↑ Good Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+30%)	14.5% Fair ↑ Fair Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+21%)	14.1% Fair Fair Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+18%)	12.7% Fair Fair Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+6%)
FCF Margin (%) (%)	-18.0% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-5.8% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	15.1% Good ↓ Good Declining Free cash flow as a percentage of revenue Optimal: > 10%	8.0% Caution Caution Free cash flow as a percentage of revenue Optimal: > 10%	27.9% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%
FCF / Net Income (x)	-3.13x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.37x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	2.20x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗
Return on Invested Capital (%)	1.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	10.3% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	10.7% Good Good Return earned on debt + equity capital invested Optimal: > 10%	13.8% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	1.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	7.9% Fair ↓ Fair Declining Operating profit relative to total assets Optimal: > 10%	8.7% Fair Fair Operating profit relative to total assets Optimal: > 10%	10.2% Good Good Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	4.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-73%)	12.8% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-15%)	12.0% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-20%)	17.8% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+18%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗
Debt to Equity (x)	0.64x Fair ↑ Fair Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+6%)	0.39x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-35%)	0.17x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-71%)	—	—
Interest Coverage (x)	1.48x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	15.20x Excellent ↓ Excellent Declining Operating income divided by interest expense Optimal: > 5x	539.06x Excellent ↑ Excellent Improving Operating income divided by interest expense Optimal: > 5x	44.91x Excellent Excellent Operating income divided by interest expense Optimal: > 5x	8.71x Good Good Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$18.84M	$11.32M	$4.11M	—	—
Debt / EBITDA (x)	22.12x Weak ↑ Weak Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	2.92x Fair Fair Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	1.33x Good Good Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗
Revenue per Share (USD)	$0.13	$0.15	$0.14	$0.14	$0.15
Basic EPS, GAAP (USD)	$0.01	$0.02	$0.02	$0.02	$0.02
Free Cash Flow per Share (USD)	$-0.02	$-0.01	$0.02	$0.01	$0.04
Book Value per Share (USD)	$0.19	$0.18	$0.15	$0.11	—
Tangible Book Value per Share (USD)	$0.19	$0.18	$0.15	$0.11	—
Basic Weighted Avg Shares (shares)	156.55M	156.47M	145.14M	135.00M	135.00M

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗
Working Capital (USD)	$20.35M	$25.66M	$22.19M	$13.20M	—
Total Equity (USD)	$29.64M	$28.82M	$23.98M	$15.24M	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Sep 30, 2025 20-F ↗	FY 2024 Sep 30, 2024 20-F ↗	FY 2023 Sep 30, 2023 20-F ↗	FY 2022 Sep 30, 2022 20-F ↗	FY 2021 Sep 30, 2021 20-F ↗
Sales/Revenue/Turnover (USD)	$20.69M	$23.50M	$19.82M	$19.19M	$20.76M
Depreciation Expense (USD)	$243.40K	$237.82K	$225.90K	$362.60K	$346.61K
Net Income, GAAP (USD)	$1.19M	$3.68M	$2.88M	$2.71M	$2.63M
Operating Cash Flow (USD)	$2.90M	$-1.21M	$3.11M	$1.58M	$5.84M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 4 quarters

Jin Medical International Ltd.

Analytical Summary

5-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare ZJYL with peers